Fungi · Scientific monograph
Lentinula edodes
Shiitake
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Immunological Research, Cardiovascular System, Microbial Research
Research overview
Historical use
Cultivated and used as food and medicine in China and Japan for over 1,000 years. Referenced in Chinese medical texts as early as 100 CE (Liu Ming Ben Cao). Traditionally used for improving vitality, treating colds, liver conditions, and as an aphrodisiac. The most widely cultivated edible mushroom globally.
Modern research context
Lentinan, the primary beta-glucan, is approved in Japan as an adjunct in gastric cancer treatment (IV formulation) [5]. AHCC (Active Hexose Correlated Compound), derived from shiitake mycelium, is studied for NK and T-cell enhancement [2] and has demonstrated tumour growth inhibitory activity in patient-derived xenograft models [3]. A randomised controlled trial evaluated AHCC supplementation for clearance of persistent HPV infections [1]. Adjuvant use following hepatic resection for hepatocellular carcinoma has been investigated [4]. Immunomodulatory polysaccharides engage innate immune pathways via pattern recognition receptors [5].
Adverse effects
Shiitake dermatitis (flagellate erythema) — a distinctive linear skin rash triggered by consumption of raw or undercooked mushroom (due to lentinan). GI upset. Eosinophilia reported. Rare hypersensitivity pneumonitis with occupational exposure (spore inhalation).
Contraindications
Known shiitake allergy (dermatitis risk). Avoid concurrent use with immunosuppressants. Caution with anticoagulants.
Clinical and phytochemical data
Used part
Fruiting body and mycelium
Primary active compounds
Lentinan (beta-1,3/1,6-glucan)
Eritadenine (2(R),3(R)-dihydroxy-4-(9-adenyl)-butyric acid)
AHCC (alpha-glucan-rich, from mycelium)
KS-2 (alpha-mannan peptide)
Polysaccharides
L-ergothioneine
Mechanism of action
Lentinan activates macrophages, NK cells, and T-cells via Dectin-1 and complement receptor 3 (CR3). Upregulates IL-12, TNF-α, IFN-γ. Eritadenine competitively inhibits S-adenosylhomocysteine hydrolase, lowering plasma homocysteine and LDL-cholesterol. AHCC activates NK and dendritic cells and modulates alpha-glucan-dependent pathways.
Pharmacokinetics
Absorption
Absorption is compound-dependent. L-ergothioneine (abundant in shiitake) is avidly absorbed after oral administration in healthy humans, with significant elevations in plasma and whole blood concentrations [1]. Lentinan (beta-glucan) has limited oral bioavailability; intestinal uptake in animal models occurs via clathrin-mediated endocytosis and macropinocytosis [3]. No human oral bioavailability data for lentinan are currently available.
Distribution
L-ergothioneine distributes extensively into whole blood and erythrocytes after oral dosing in humans, with high blood-to-plasma concentration ratios reflecting active cellular uptake via the OCTN1 transporter [1]. Lentinan was detected and quantified in the blood of 10 healthy volunteers and cancer patients using a limulus colorimetric assay, confirming systemic exposure [2]. Distribution of polysaccharide fractions (beta-glucans) to immune-associated tissues (spleen, gut-associated lymphoid tissue) is inferred from preclinical data.
Metabolism
L-ergothioneine is partially metabolised in humans; whole blood levels of hercynine and S-methyl-ergothioneine were found to correlate with ergothioneine concentrations following oral dosing in healthy subjects, indicating in vivo biotransformation [1]. Lentinan and other polysaccharides are largely resistant to gastric and intestinal enzymatic degradation; microbial fermentation in the colon produces short-chain fatty acids (SCFAs). No human metabolic data for lentinan are available — preclinical data only.
Excretion
L-ergothioneine is excreted primarily via non-renal routes in humans; urinary excretion accounts for less than 4% of the administered oral dose, consistent with avid bodily retention [1]. Renal and biliary excretion pathways for lentinan and other polysaccharides have not been characterised in humans — preclinical (rat) data only [3].
Safety and interactions
Drug interactions
Lack of clinical studies prevents interaction grading. Unknown safety profile with concomitant drug use.
Toxicity
Lentinan IV: well tolerated; eosinophilia reported in some trials. Oral whole mushroom is well tolerated at dietary quantities, with dermatitis from raw mushroom consumption being the most clinically relevant adverse effect. Long-term safety data for concentrated extract preparations are limited.
Special precautions
Pregnancy
Dietary consumption considered safe. Medicinal doses (concentrated extracts) — insufficient data; avoid.
Lactation
Dietary quantities considered acceptable. Concentrated supplemental doses — insufficient data.
Hepatic impairment
No hepatotoxicity has been documented in available clinical studies. AHCC has been studied as an adjunct in hepatitis C patients without evidence of hepatic adverse effects; standard monitoring is recommended with concentrated preparations due to limited long-term data in the setting of hepatic disease.
Renal impairment
No specific risk identified. No dose adjustment data available.
Sources and references
- [1] - Smith JA., "AHCC® Supplementation to Support Immune Function to Clear Persistent Human Papillomavirus Infections.", Front Oncol, 2022, PMID: 35814366
- [2] - Shin MS., "The Effects of AHCC®, a Standardized Extract of Cultured Lentinura edodes Mycelia, on Natural Killer and T Cells in Health and Disease: Reviews on Human and Animal Studies.", J Immunol Res, 2019, PMID: 31930148
- [3] - Yoshii R., "The Tumor Growth Inhibitory Effect of a Standardized Extract of Cultured Lentinula edodes Mycelia Using Patient Derived Xenograft Model.", Biol Pharm Bull, 2024, PMID: 38417905
- [4] - Kamiyama T., "Preventing Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy With Active Hexose-correlated Compound Derived From Lentinula edodes Mycelia.", Integr Cancer Ther, 2022, PMID: 35075934
- [5] - Roszczyk A., "Immunomodulatory Properties of Polysaccharides from Lentinula edodes.", Int J Mol Sci, 2022, PMID: 36012249